Physician profile
Craig Roberto
NPI 1760655203
$33,250.92
in general payments reported to CMS, 2019-2025
22 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,075 · 2020: $3,056 · 2021: $3,653 · 2022: $10K · 2023: $3,925 · 2024: $2,967 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,318 · Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,317.81 |
| Food and Beverage | $2,029.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prodigy Surgical Distribution, INC. | $23,173.32 | 2019-2025 | |
| Arthrex, INC. | $7,166.28 | 2019-2025 | |
| Pacira Therapeutics, INC. | $859.00 | 2019-2021 | |
| Stryker Corporation | $746.03 | 2019-2025 | Insignia, Mako |
| Ferring Pharmaceuticals INC. | $328.57 | 2019-2023 | Euflexxa |
| Smith+Nephew, INC. | $227.32 | 2019-2025 | Bone Anchors With Arthroscopic Delivery System, Firstpass, Healicoil |
| Horizon Therapeutics Plc | $163.63 | 2019-2022 | |
| Bioventus LLC | $114.74 | 2019-2025 | Gelsyn-3 |
| Takeda Pharmaceuticals U.S.A., INC. | $92.02 | 2024 | Entyvio |
| Pacira Pharmaceuticals Incorporated | $55.90 | 2020-2022 | |
| Fidia Pharma USA INC. | $48.79 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $47.75 | 2022-2023 | Seglentis |
| Nevro Corp. | $30.55 | 2019 | |
| Avanos Medical | $29.89 | 2024 | Trivisc Sodium Hyaluronate |
| Medtronic USA, INC. | $29.38 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $27.12 | 2025 | Monoferric |
| Convatec INC. | $22.56 | 2023 | |
| Lundbeck LLC | $20.65 | 2025 | Vyepti |
| Ardelyx, INC. | $17.93 | 2024 | Ibsrela |
| Depuy Synthes Sales INC. | $17.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.36 | 2019 | |
| Lilly USA, LLC | $14.75 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Roberto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.